Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss

Deep brain stimulation of the subthalamic nucleus (STN-DBS) is efficacious in treating the motor symptoms of Parkinson's disease (PD). However, the impact of STN-DBS on the progression of PD is unknown. Previous preclinical studies have demonstrated that STN-DBS can attenuate the degeneration of a relatively intact nigrostriatal system from dopamine (DA)-depleting neurotoxins. The present study examined whether STN-DBS can provide neuroprotection in the face of prior significant nigral DA neuron loss similar to PD patients at the time of diagnosis. STN-DBS between 2 and 4 weeks after intrastriatal 6-hydroxydopamine (6-OHDA) provided significant sparing of DA neurons in the SN of rats. This effect was not due to inadvertent lesioning of the STN and was dependent upon proper electrode placement. Since STN-DBS appears to have significant neuroprotective properties, initiation of STN-DBS earlier in the course of PD may provide added neuroprotective benefits in addition to its ability to provide symptomatic relief.

[1]  R. P. Maguire,et al.  Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  R. Faull,et al.  Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson’s disease , 2008, Neuroscience.

[3]  N. Muzyczka,et al.  Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer , 1999, Brain Research.

[4]  H. Steinbusch,et al.  Protection of nigral cell death by bilateral subthalamic nucleus stimulation , 2006, Brain Research.

[5]  A. Benabid,et al.  Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. , 2007, Brain : a journal of neurology.

[6]  F. Windels,et al.  Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat , 2000, The European journal of neuroscience.

[7]  A. Björklund,et al.  Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat , 1996, Neuroscience.

[8]  M. Pisa.  Motor somatotopy in the striatum of rat: Manipulation, biting and gait , 1988, Behavioural Brain Research.

[9]  J. Kordower,et al.  Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys , 2006, Annals of neurology.

[10]  A. Rodriguez-Perez,et al.  The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease , 2009, Journal of neurochemistry.

[11]  K. Paumier,et al.  Transplantation of subventricular zone neural precursors induces an endogenous precursor cell response in a rat model of Parkinson's disease , 2009, The Journal of comparative neurology.

[12]  J. Volkmann.  DEEP BRAIN STIMULATION II Deep Brain Stimulation for the Treatment of Parkinson’s Disease , 2004 .

[13]  T. Schallert.  Behavioral tests for preclinical intervention assessment , 2006, NeuroRX.

[14]  C. Shults,et al.  BDNF attenuates the effects of intrastriatal injection of 6‐hydroxydopamine , 1995, Neuroreport.

[15]  G. Stebbins,et al.  Differential progression of motor impairment in levodopa‐treated Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[16]  A. Benabid,et al.  Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 2003, The New England journal of medicine.

[17]  J. Koprich,et al.  Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. , 2003, Brain research. Developmental brain research.

[18]  J. Mink,et al.  Cortical and subcortical blood flow effects of subthalamic nucleus stimulation in PD , 2003, Neurology.

[19]  H. Klüver,et al.  A method for the combined staining of cells and fibers in the nervous system. , 1953, Journal of neuropathology and experimental neurology.

[20]  Jianguo Zhang,et al.  Change of Extracellular Glutamate and Gamma-Aminobutyric Acid in Substantia Nigra and Globus Pallidus during Electrical Stimulation of Subthalamic Nucleus in Epileptic Rats , 2008, Stereotactic and Functional Neurosurgery.

[21]  M. García-Arencibia,et al.  Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties , 2007, Brain Research.

[22]  Anders Björklund,et al.  Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.

[23]  A. Kupsch,et al.  Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism , 2008, Experimental Neurology.

[24]  A. Lozano,et al.  Neural stimulation for Parkinson’s disease: current therapies and future directions , 2006, Expert review of neurotherapeutics.

[25]  S. Wiegand,et al.  Efficacy of Brain‐Derived Neurotrophic Factor and Neurotrophin‐3 on Neurochemical and Behavioral Deficits Associated with Partial Nigrostriatal Dopamine Lesions , 1994, Journal of neurochemistry.

[26]  M. Savasta,et al.  Subthalamic Stimulation-Induced Forelimb Dyskinesias Are Linked to an Increase in Glutamate Levels in the Substantia Nigra Pars Reticulata , 2006, The Journal of Neuroscience.

[27]  B Conrad,et al.  A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. , 1999, Archives of neurology.

[28]  J. Labandeira-Garcia,et al.  Time-Course of Brain Oxidative Damage Caused by Intrastriatal Administration of 6-Hydroxydopamine in a Rat Model of Parkinson’s Disease , 2006, Neurochemical Research.

[29]  Deepti Mathur,et al.  Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease. , 2006, Indian journal of experimental biology.

[30]  M. Beal,et al.  Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.

[31]  A. Kelley,et al.  Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum , 2004, Psychopharmacology.

[32]  M. Mouradian.  Recent advances in the genetics and pathogenesis of Parkinson disease , 2002, Neurology.

[33]  J. Cavanaugh,et al.  Differential Metabolic Activity in the Striosome and Matrix Compartments of the Rat Striatum during Natural Behaviors , 2002, The Journal of Neuroscience.

[34]  F. Coppedè,et al.  Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. , 2009, Mutation research.

[35]  F. Ebner,et al.  The contribution of the principal and spinal trigeminal nuclei to the receptive field properties of thalamic VPM neurons in the rat , 2004, Journal of neurocytology.

[36]  W. Cass,et al.  Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson’s disease , 2007, Neuroscience.

[37]  R. Ridley,et al.  Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease , 2005, The Journal of Neuroscience.

[38]  J. Kordower,et al.  Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. , 2003, Neurotoxicology and teratology.

[39]  J. Kordower,et al.  In vivo gene therapy as a potential treatment for Parkinson's disease , 2006 .

[40]  S. Gauthier,et al.  Environment, Genetics and Idiopathic Parkinson's Disease , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[41]  Lingxin Kong,et al.  Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease , 2005, Brain Research.

[42]  C. Dufouil,et al.  Interaction between genes and environment in neurodegenerative diseases. , 2007, Comptes rendus biologies.

[43]  G. Nappi,et al.  Time‐course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6‐hydroxydopamine in the rat: new clues from an old model , 2007, The European journal of neuroscience.

[44]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[45]  N. Kumar,et al.  Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .

[46]  J. Parga,et al.  The Mitochondrial ATP-Sensitive Potassium Channel Blocker 5-Hydroxydecanoate Inhibits Toxicity of 6-Hydroxydopamine on Dopaminergic Neurons , 2009, Neurotoxicity Research.

[47]  Anne Bertrand,et al.  Influence of the frequency parameter on extracellular glutamate and γ‐aminobutyric acid in substantia nigra and globus pallidus during electrical stimulation of subthalamic nucleus in rats , 2003, Journal of neuroscience research.

[48]  Patrik Brundin,et al.  Restorative Therapies in Parkinson's Disease , 2006 .

[49]  W. Duan,et al.  Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson’s disease , 2007, Neuroscience.

[50]  J. Parga,et al.  Mechanism of 6‐hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6‐hydroxydopamine‐induced degeneration of dopaminergic neurons , 2007, Journal of neurochemistry.

[51]  O. Hornykiewicz.  Neurochemical pathology and the etiology of Parkinson's disease: basic facts and hypothetical possibilities. , 1988, The Mount Sinai journal of medicine, New York.

[52]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[53]  D. Marchionini,et al.  Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons , 2007, Journal of Neuroscience Methods.

[54]  Y. Kajita,et al.  Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. , 2004, Journal of neurosurgery.

[55]  Y. Agid,et al.  Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[56]  G. Petzinger,et al.  The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.